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Coronary artery disease (CAD) is the major cause of fatality and disability among all car-
diovascular diseases (CVD). Intricate interactions of genes and environment dictate the
outcomes of CAD. Technological advances in the different fields of genetics including
linkage studies (LS), candidate gene studies (CGS) and genome-wide association studies
(GWA studies) have augmented the knowledge of pathogenesis of CAD. LS were more
successful in identifying genetic variants among monogenic disease. GWA studies were
relatively popular in identification of variation in polygenic disease. Until now, GWA
studies recognized about 50 loci determining around 6% of the heritability in CAD. Clinical
utility of the above knowledge would result in better CAD management, but validation of
the variants in native population is warranted for active adoption into the clinic. The major
aim of this review is to provide an adequate perspective of our current understanding and
advances of genetics in CAD.
Copyright © 2014, Cardiological Society of India. All rights reserved.1. Introduction
Coronary artery disease (CAD) has reached epidemic pro-
portions and is the significant cause of death among Cardio-
vascular Diseases (CVD).1,2 Around three and half million
Indians, both men and women had became victim to death
due to CAD.3e5 Further, CAD occurs ten years earlier in Indians
when compared to thewestern populationwith 50% occurring
in individuals below 50 years and 25% in individuals below the
age of 40 years.5,6 Moreover, 40e50% of subjects with CAD doent, Apollo Hospitals, Hy
(S. Naik).
ociety of India. All rightsnot have any associated risk factors.6 It is now universally
accepted that CAD has a significant hereditary component,
especially in the younger generation, and is widely reported
in published studies, including familial, twin-concordance,
pedigree, and adoption studies.7e12
Delineation of genetic factors associated with CAD is best
studied in a phased manner. The primary phase entails
recognition of the inheritable component/s of CAD. The sec-
ondary phase involves teasing the genetic framework of CAD,
i.e., identification of exclusive loci, and the transmissiblederabad, India. Tel.: þ91 (0) 40 23556622.
reserved.
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incidental phase is the most complicated aspect of the whole
genetic characterization of CAD.
Basing on the apparent patterns of inheritance, genetic
diseases are classified into twobroad categories i.e.monogenic
and polygenic forms. In the monogenic form of disease, fa-
milial variation in one gene is responsible for all or the major
part of the disease incidence. Polygenic diseases, group gene
variants are responsible for the intricate patterns of inheri-
tance. Their interplay with each other often results in negli-
gibleeffectand their interplaywithanumberof environmental
factors leading to the outcome.2. Historical and current understanding of
CAD genetics
Our apprehension about the genetic framework of CAD has
pronouncedly increased since 2007, when the first GWA
studies in CAD were reported and a brief overview of the his-
toricalmilestones in CAD genetics is documented in Table 1. A
whole scale of intricate differences was identified in human
genome. These differences range from single nucleotide
polymorphisms (SNPs) to large variations such as deletions,
insertions, translocations, and copy number variations. The
original approach of research before 2000 was through anal-
ysis of inheritance patterns in susceptible families, through
genetic LS. Positive results were obtained in identification of
genetic variants in single gene disorders. For complicated
diseases, the aforementioned approach was not so beneficial.
This paved the way for introduction of GWA studies, used to
catechize common genetic variants in diverse individuals
associated with a particular trait. Two preliminary GWA
studies in CAD were published concurrently in 2007, which
documented the role of 9p21 loci in myocardial infarction (MI)
and CAD; a third study later reproduced the above
findings.13e15 Our understanding of the genetic framework of
CAD has significantly improved from the above studies.Table 1 e Historical milestones in genetics and CAD
genetic studies.
1953 J.D Watson and F.H Crick delineated the molecular
structure of nucleic acid
1968 Deciphering of the genetic code
1975 DNA sequencing
1977 Development of electrophoretic methods for DNA
sequencing
1983 Polymerase chain reaction
1987 First human genetics map using restriction enzyme
digestion
2001 Initial sequencing and analysis of Human Genome.
2005 Detailed map of SNP variants by International HAP
MAP project
2006 First computerized microarray assembled. Preliminary
report of gene interrelation with an attribute using
GWA studies
2007 Two SNPs at 9p21 associated with MI and CAD by GWA
studies
2010 GWA studies described CVD risk factors
(95 loci related with lipids, 30 loci with BMI and obesity)
2011 GWA studies reported >30 gene loci associated with CADIn early 2013, a meta-analysis study listed 50 genetic vari-
ants associated with CAD. These variants explainmore or less
6% of the inheritance effect transmitted in CAD. Most of these
variants are associated with triglyceride-metabolism, hyper-
tension, and inflammation, suggesting their role in the path-
ogenesis of CAD. Interestingly, the above study found no
overlap between the CAD loci, and those affiliated with Type-
2diabetes.16,17 Moreover, most of these CAD loci are located in
intragenic regions of the genome with unknown functions.3. Coronary atherosclerosis and
atherothrombosis
The various genetic markers associated with CAD discovered
through studies can be grouped into four major biological
pathways. These pathways are responsible for the pathogen-
esis of lipid disorders, endothelial dysfunction, arterial
inflammation, and thrombosis.18,19
i. Familial Hypercholesterolemia (FH): High levels of LDL in
the blood characterize FH, which is often present as
tendon and joint xanthomas. Numerous studies have
demonstrated the role of lipid irregularities, mainly altered
levels of LDLeC as a risk factor for CAD. Although FH is
often diagnosed by evidence of high LDL levels and family
history of premature heart disease, the unequivocal diag-
nosis of FH is done through genetic testing. FH is most
usually transmitted as an autosomal co-dominant trait.20
a. Autosomal Dominant e Loss-of-function deviation in
the LDLereceptor gene results in autosomal dominant
form of FH. Overall, there have been more than 800
different documented mutations involving the LDLeR
gene. This receptor is found on the surface of all nucle-
ated cells, butmainly in the liver. LDL receptors facilitate
the uptake and degradation of LDL from the circulation.
As such, mutations to the LDL receptor lead to higher
plasma levels of LDL.21 There are two forms of FH e
homozygous and heterozygous. The homozygous form
is rare with a frequency of less than 1/106, is associated
with a complete absence of the LDL receptor, and can
lead to four times the normal LDL value. About 40% of
FH, homozygotes may develop CAD before the age of 20.
They generally do not respond to dietary or drug treat-
ment. The heterozygous form with a frequency of about
1 in 500 in most populations can cause an elevation in
LDL levels of about twice the normal value. The hetero-
zygous forms do respond to dietary and drug treatment.
Apogene: ApoB that encodes Apo lipoprotein (ApoB) is also
involved inautosomaldominant transmissionof FH. It is by the
recognition and binding of ApoB on the surface of LDL particles
that the LDL receptor is able tomediate the endocytosis of LDL
from circulation. Unlike the over 800 LDL-R mutations that
were documented, there have been only two variants found on
ApoB. The prevalence of mutation in this gene is 1 in 100.
Clinically, a phenotype caused by an ApoBmutation cannot be
distinguished from that caused by LDLeR mutation, although
the former tends to be less severe as the defective ApoB allele
exhibits incomplete penetrance. It should be noted that some
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as familial defective ApoB 100 (FDB) rather than FH.22
PCSK-9 gene: PCSKe9 is the most recent entry found to be
responsible for the autosomal dominant transmission of FH.
Although the mechanism is not completely understood it is
thought that PCSK e 9 is a serine protease that is involved in
the regulation of blood cholesterol levels by breaking down
the LDL receptors within the liver cells before they are able to
reach the surface. Mutations in this gene are relatively rare
with a prevalence of less than one in 2500.22
b. Autosomal Recessivee LDLRAP1 An autosomal recessive
form of hypercholesterolemia referred to as autosomal
recessive hypercholesterolemia (ARH), has also been
found in a small number of patients with hypercholes-
terolemia. Only one gene LDLRAP1 has been implicated
in ARH. LDLRAP1 encodes LDL receptor adaptor protein 1
which is required for endocytosis of LDL particles by
liver cells.21
Cholesterol 7a-hydroxylase deficiency is also a rare auto-
somal recessive disease that causes high cholesterol and tri-
glyceride levels.224. Landscape of genetic studies in CAD
Interplay of many factors is relevant in the manifestation of
disease including lifespan, gender, gene pool, and environ-
ment. There is considerable variability in susceptibility and
expression of disease even with the same degree of exposure/
time of environmental risk factors. This considerable vari-
ability is due the individual's unique geneticmake-up, or some
other potentiating risk factor or the interplay of factors among
them. Genetic landscape studies in CAD are generally con-
ducted by two most popular approaches, i.e. linkage studies
(LS) and association studies (AS).
i. Linkage studies (LS) e LS involves identification of genetic
variants among individuals of affected families for many
generations. LS usually commence by recognizing genetic
markers, leading to either a gene or gene variant (SNP) of
interest. LS are exemplary studies for pin-pointing disease
risk site across the genome, and can be used to study
different genetic markers concurrently.17 The major
drawback of LS is that researchers need to pool a large
number of afflicted families in generation. In addition, LS
hold good for study of single genes only and not when
multiple genes are involved.
LS in CAD yielded mixed results among diverse population
studies. Genomic regions/loci from published LS is largely
non-overlapping, implicating genetic and or phenotypic di-
versity. The original fine mapping LS yielded two genes, i.e.
ALOX5AP and MEF2A. Different Haplotypes of the ALOX5AP
gene in the Icelandic locus corresponded with CAD in the
population-based studies of Iceland/England. The same Ice-
landic haplotype was linked to stroke in Iceland and Scot-
land.23 Another transcription factor expressed in coronary
artery endothelium Myocyte enhancer factor 2A (MEF2A) wasidentified by LS in a pedigree analysis in which 13 individuals
had CAD, nine had MI.23
ii. Association studies (AS) e These studies assess the corre-
lation between genetic variants, either single nucleotide
polymorphisms (SNPs)/copy number variations (CNVs).17
The most common and significant limitations of these
studies are defining the phenotype to be studied and re-
duplication of the findings among different populations. In
addition, to recognize genetic variants with minor effects,
large population sizes are required. This is obtained by
pooling different samples and populations. There are
several types of AS, which are outlined below:
a. Candidate gene studies (CGS) e CGSare generally used
for study of complicated diseases with transitional
traits. This approach is based on an a-priori postulation
generated from knowledge of disease pathogenesis and
or leads from preceding studies. Many CGS analyzing
the correlation between genetic variants and pheno-
types were published. The major limitation of these
studies is the reproduction and reduplication of the
results.
b. Genome-Wide Association Study (GWA study) e The
majorobjectiveofGWAstudies is to recognizehereditary
variants correlating with complex phenotypes, without
the prior selection of candidate loci or genes. GWA
studies rely majorly on two presumptions: primarily, a
greater part of variation in the genome can be explained
by a relatively smaller number of genetic variants and
second; complex diseases are predominantly generated
by close interaction of common genetic variants.17 GWA
studies became accomplishable through technological
breakthroughs allowing large numbers of SNPs to be
genotyped simultaneously. Moreover, overwhelming
and robust association analysis algorithms have also
been developed to encompass and interpret the above
information in a structured manner.12
Simultaneously, international collaborations and consortia
in the field of GWAS research in CAD have provided new
impetus in CVD pathogenesis. While, the total number of
research studies that use GWA studies in CAD has expanded
expeditiously in recent years, significant challenges still exist
using the GWAS. The major challenges includes defining case
e control groups, controls for multiple testing and population
stratification issues and the large number of statistical tests
involved, which may lead to false positives. However, these
studies have constantly identified significant loci in scores of
clinically important CAD phenotypes.245. International Genome-Wide Association
Studies of CAD
9p21 was uncovered in two diverse populations, in the Well-
come Trust namely the British Case Control Consortium
(WTCCC) and the German MI Family Study (GerMIFS).25
Around the same time it was reported that this particular
locus on chromosome 9 was consistently associated with
CAD.13 This CAD associationwith 9p21.3 represents one of the
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studies strata. This result has been duplicated in several in-
dependent samples and ethnic populations including the Eu-
ropean, Korean, and Japanese. In addition, studies have
shown that 9p21.3 locus is also associated with a variety of
vascular phenotypes such as abdominal aortic aneurysms,
intracranial aneurysms, and peripheral arterial disease.15
Soon it was realized that to identify the modest effects of
risk variants in CAD, a larger population sample size is needed.
For example, detecting a variant that bestows a risk of 10%,
existing in15% of the population, necessitates a representative
sample size of 20,000 to contribute a 80% statistical power and
almost a similar sample size would be needed for replication
studies.26 These huge requirements favored the formation of
international groups to pool resources and form consortia.11
The two major consortia formed are the CARDIoGRAM
(Coronary Artery Disease Genome-wide Replication andMeta-
analysis) in 2010 & Coronary Artery Disease (C4D) Genetics
Consortium in 2011.16 These consortia reported 13 novel sus-
ceptibility loci correlating with CAD and MI. Cardiogram &
C4D identified four additional novel loci in individuals with
European and South Asian ancestry.18 Together, these con-
sortia having evaluated more than 200,000 individuals have
identified and replicated more than 30 novel loci for CAD.26
Approximately 10% of the heritability of CAD is explained by
the 50 genetic loci discovered so far. It has been shown that
eight of the 50 loci belong to lipid metabolism and blood pres-
sure regulation pathways. An overview of the major GWAS
studiesare compiled inTable 2. Further theadditional identified
loci do not correlate with any of the present known risk factors
in CAD.17 This aspect is very essential to know; as it indicates
that there are other pathways and unknown pathophysiolog-
ical,mechanismsare yet to beelucidated further.27Newgenetic
analysis tools can shed light on the identified loci and their role
in the susceptibility, progression, and or development of CAD.
The following prototypes demonstrate the promise and poten-
tial, as well as the challenges this field presents.
i. 9p21 Locus and CAD e Correlation of 9p21 locus with CAD
and MI has been evident in almost all major GWA studies
published including a meta-analysis, which implies at
least, that this correlation is widely distributed and evident
in the pathogenesis of CAD. 9p21 lies in the intragenic re-
gion, near to the group of cell-cycle regulating tumor sup-
pressor genes (CDKN2A and CDKN2B).28 The above genes
have been shown to be involved in progression of athero-
sclerosis, their role in secretion of transforming growth
factor. The 9p21 risk is not connected with known cardiac
risk factors, implicating a novel mechanism for CAD
pathogenesis and the many more to be discovered subse-
quently.28 This risk allele is seen in European, Chinese,
Korean, Japanese, Indian, and Pakistani ethnic groups,11
and its presence is correlates with a two-fold increase in
early CAD onset. It is observed that 9p21.2 dosage is also
responsible for the severity of CAD.29 Left main coronary
and multiple coronary arterial diseases were also shown
associated with a high dosage of 9p21.3 risk allele.6
The ADAMTS7 risk allele has an action on the vascular
wall and is involved in the pathogenesis of coronaryatherosclerosis.30 It is also shown that ABO blood group locus
as a risk factor for MI in the same study. The study was done
on 4372 patients with angiographic evidence of MI compared
with angiogram-documented CAD without MI. A genetic
marker at 9q34.2 showed correlation with MI but not with
CAD.11 The blood group AB and O have a single locus at 9q34.2.
It is well accepted that blood group O has some protection
from MI as compared with other blood groups. The A and B
gene transcribesa protein which transfers carbohydrate mol-
ecules on to the von Willebrand factor making them suscep-
tible to coronary thrombosis, whereas the O group gene,
encodes a protein which is abnormal and thereby decreases
the risk of MI.30
ii. Association of known risk factors with GWA studies e
While, the molecular pathways/genes through which
these genetic variants intervene and their risk remains to
be discovered, the positive results from the above GWAs-
tudies have clearly indicated that the novel genetic vari-
ants do exist and waiting to be characterized. Conduction
of GWAS studies provided the incentive in the form of
recognition of brand new molecular pathways through
which the risk is expressed. All the 50CAD loci discovered
until now do not work through known mechanisms and
new pathways are waiting to be discovered. The usage of
these pathways to discover new targets for drug therapy
should be a worthwhile pursuit. These findings also un-
derline the prerequisite of identifying genetic risk factors
to provide exhaustive data useful in the prevention and
treatment of CAD.
iii. Salient features of GWA studies in CAD e The following
are the main features of the GWA studies in CADB In early onset CAD, genetics association exhibits higher
risk than for those with late onset CAD.
B Genetic association is consistent across various ethnicities
and for both genders. However, the South Asian popula-
tion group data are inadequate.
B Vascular phenotype (defined by angiography >50%
obstruction) andMI have been shown to have different loci,
namely 9p21.3 for vascular phenotype and 9q34.2 with
MI.
B Only eight loci are associated with known risk factors like
lipids and hypertension.
B Role of novel loci in risk prediction and for therapeutic and
preventive intervention needs further study.
B Presently, routine genetic testing for primary prevention of
CAD is not recommended.6. Indian CAD studies
The majority of Indian studies are conducted in urban areas.
Prevalence of CAD in urban adults has increased four-fold in
Table 2 e Summary of major international GWA studies.
Author/year Study details Results
Samani, et al, 200714 This study Identifies correlation of specific genetic loci to CAD and MI
susceptibility.
9p21.3 (SNP, rs1333049) loci have been identified in both WTCCC and
German studies
McPherson R, et al, 200713 GWA studies identifies associations in CHD 9p21 association was identified with CHD in the Caucasian population
Helgadottir A, et al, 200715 GWA studies confirms association between MI and variant 9p21 CDKN2A and CDKN2B, tumor suppressor genes, adjacent to 9p21
variant were linked with MI
Kathiresan S, et al, 200927 GWA studies testing associates SNPs and CNVs with early-onset
myocardial infarction.
SNPs at nine loci reached significance:
Three were newly identified
21q22 near MRPS6-SLC5A3-KCNE2,
6p24 in PHACTR1,
2q33 in WDR12 and
Six replicated prior observations
9p21,
1p13 near CELSR2-PSRC1-SORT1,
10q11 near CXCL12,
1q41 in MIA3,
19p13 near LDLR and
1p32 near PCSK9
Coronary Artery Disease (C4D)
Genetics Consortium, 201116
Meta-analysis of four large GWAS of CAD implicates new pathways for CAD
susceptibility.
This study recognized five new loci associated with CAD (p < 5  108)
LIPA on 10q23
PDGFD on 11q22
ADAMTS7-MORF4L1 on 15q25, a gene rich locus on 7q22 and
KIAA1462 on 10p11.
SchunkertetH, et al, 201124 Meta-analysis of 14 GWAS of CAD in European descent individuals. This study identified 13 new loci (p < 5  108) associated with CAD.
Preus M, et al, 201038 Genome-wide reproduction and meta-analysis (CARDIoGRAM) consortium
formed, to improve the chance of finding novel predisposition loci for CAD
and MI.
9p21 variant, rs1333049 was found in the meta-analysis and accorded
a 29% increase in risk for MI per copy (p ¼ 2  1020).
Xiangfeng L, et al, 201239 Meta-analysis of 2 GWA Studies of CAD presents new understanding into
novel pathways, contributing to the susceptibility for CAD in the Chinese
Han population.
Four new loci (p < 5  108) were recognized in CAD. These loci
mapped in or near TTC32-WDR35, GUCY1A3, C6orf10-BTNL2, and ATP2B1.
The CARDIoGRAM plus C4D
Consortium, Deloukas P, et al, 201240
This study provides hereditary basis of CAD and identifies major biological
pathways.
15 significant loci were recognized, increasing the number of CAD
susceptible loci to 46. The above loci belong to the Lipid metabolism
and inflammation networks.
ReillyM P, et al, 201130 Study identifies that specific genetic predispositions promote the development
of coronary atherosclerosis whereas others lead to MI.
Novel ADAMTS7 and ABO loci were recognized with independent
roles in CAD pathogenesis.
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i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 6 6 3e6 7 1668the last 40 years, and even in rural areas, it has doubled.2 The
factors responsible for increased prevalence in CAD in India
include adoption of unhealthy lifestyles, increased tobacco
consumption, and socioeconomic transitions associated with
urbanization and industrialization. With evidence of the
increasing prevalence of CAD during the past two decades
among Indians and Indian emigrants in other countries, a
large number of GWA studies have been conducted.5 Many of
the candidate gene polymorphisms reported in Western
studies have been replicated in Indians.
Despite intrinsic difficulties in the design and execution of
GWA studies, two recent studies attempted sib pair analysis in
order to determine the familial nature of CAD. The Indian
AtheroscleroticResearchStudy (IARS),ageneticstudyexploring
the molecular basis of CAD in Indian families with a strong
familial history.31 Another group from the National Institute of
Biomedical Genomics (NIBMG), Kolkata, screened for 209 SNP
markers in 31 genes for ten quantitative traits like Apo lipo-
protein B (ApoB), C-reactive protein (CRP), fibrinogen (FBG),
homocysteine (HCY), lipoprotein (a) (LPA), cholesterol-total
(CHOL-T), cholesterol-HDL (CHOL-H), cholesterol-LDL (CHOL-
L), cholesterol-VLDL (CHOL-V), and triglyceride (TG) in 144 nu-
clear families of a homogenous Marwari population from Kol-
kata.32 Through Q-TDT analysis, nine SNPs were discovered in
four genes e SELE, VEGFA, FBG, and NFKB1 have a meaningful
impact on quantitative precursors of CAD. An overview of the
major indian genetic studies in CAD with referenced genes is
compiled in Table 3.
Concerning the number of genes linked with CAD world-
wide, the CGS conducted so far on Indian populations is
insufficient to draw any conclusions. Nevertheless, the asso-
ciation of the prominent locus 9p21.3 found in international
GWA studies is replicated for three SNPs, rs10116277,
rs1333040 and rs2383206inNorth Indians and two SNPs,
rs2383207 and rs10757278, in the South Indian population.33
This 9p21 locus, which includes a large 53-kilobase region,
has been hypothesized to regulate expression of genesTable 3 e Major Indian genetic studies in CAD with identified
Author/year Gene
Hebbagodi S, et al, 200832 ApoA1-C3-A5 Regu
Siwach P, et al, 201041 GHRd3 Signi
Kakkar VV, et al, 201042 High levels of CRP hsCR
Kakkar VV, et al, 200943 Plasma factor 7 glu353 arg
(RR, RQ, QQ)
Signi
amon
Gupta D, et al, 20112 APoA5-1131T > C Prom
trigly
Kumar P, et al, 201044 ACEI/D Risk
Ghosh A, et al, 200845 Apo E ACE
an im
Jyothy A, et al, 2010 MMP3 5A/6A promoter gene
polymorphism
Role
Gill KD, et al, 20112 PON1 Q192R CAD
as co
Renuka Nair R, et al, 201146 PPARa Intron 7 G2528C Impa
susce
Nair KG, et al, 200647 MTHFR (Hinf1) AA, AV, VV, MS
(HaeII) (DD, DG, GG)
MS (A
with
Khan AS, et al, 201148 ACEI/D Meta
Majumder PP, et al, 201132 209 SNPs in 31 genes of 10 QTLS 9 SNPcontrolling cell proliferation pathways, leading to athero-
sclerosis.34 Hence, there is a need for an analysis of risk
conferred by this region among different ethnic groups in
India.
Apollo Hospitals has completed the first preliminary Indian
GWA study to identify the genetic basis of MI in young Indians
in collaboration with the National Institute of Biomedical
Genomics (NIBMG) and the Institute of Genomics and Inte-
grative Biology (IGIB). This unpublished study identified net-
works, canonical pathways derived from SNPs through a
pathway based approach belonging to CAD. However, this
study needs to be replicated in larger cohorts for validation.7. Clinical implication and utility
Despite the success of the GWA studies in recognizing sig-
nificant genetic associations, the translation of such findings
into clinically adept tools for CAD prognosis has only now
begun to yield fruits. Owing to the fact of the very recent and
swift discovery of multiple genes and loci for MI, care should
be taken for the use of cardiovascular genomics at the bedside.
It should be noted that despite their very strong statistical
associations with MI and the consistency of the associations
in multiple populations, SNPs associated with MI in GWA
studies have consistently shown small to modest relative
risks and explain a fraction of the heritability estimates of
CAD and only a very small proportion of the inter-individual
variance in risk of CAD (1e5%); this suggests that large
numbers of SNPs (including many rarer variants) will likely be
required for clinical utility in risk prediction. The translation
of genetic discovery into useful clinical biomarker for predic-
tion, prevention, and treatment of patients still requires
detailed studies to demonstrate these “causal” genetic vari-
ants, through sequencing of the concerned regions of the
human genome. The discovery of 50 genetic risk variants for
CAD and the augmented awareness of impediment havegenes.
Function of genes
lation of lipids.
ficant association of deletion allele GHRd3 with CAD.
P appears to be an independent predictor of recurrent CAD events
ficant association of FVIIc activity with lipid markers, Concurrently,
g those with RR and RQ genotype after covariate adjustment.
oter polymorphism in APOA5 correlated with augmented serum
cerides and that of HL with raised HDL2 levels.
factors for MI in a South Indian population.
gene insertion/deletion polymorphism has been acknowledged as
portant genetic risk factor for essential hypertension.
of MMP3 5A/6A gene is clarified in MI.
patients have down regulated PONase and AREase enzyme activities
mpared to the controls.
ired lipid metabolism in carriers of the PPARa Intron 7C risk allele is
ptible to CAD.
2756G) genotype was recognized. A significant association of HHcy
MTHFR (C677T).
bolic syndrome was associated with ACE gene polymorphism.
s from four genes SELE, VEGFA, FBG, and NFKB1 were reported.
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exploitation of their biology and pathophysiology.11
However, a number of issues remain unclear. Most of the
genetic variants have been identified preponderantly in Eu-
ropean populations, and such variants demand comprehen-
sive validation in Indian population to substantiate their
clinical utility. Second, the assessment of apparently signifi-
cant (gene-environment and geneegene) interactions has
thus far been limited and will require adequately powered
large-scale studies to delineate the role of such interactions
and their impact on risk prediction.
The actual implementation of the GWA studies results into
clinical practice is highly challenging. Knowledge of the car-
diac risk factors and genetic DNA variants together will defi-
nitely strengthen the prognosis of the disease. Risk variants
can be determined and quantified using sophisticated and
intricate algorithms already available. Well-designed ran-
domized studies will be indispensible to demonstrate that the
use of genetic information in risk predisposition, selection of
targeted drug therapies, or personalized medicine leads to
purposeful improvements in outcomes and is cost-effective.
Several studies have begun to assess the prognostic power
of the inclusion of single SNPs andmultiple SNPs in predicting
the genetic risk scores of MI.
An exciting new outcome of the genetic studies is
thePCSK9 gene, a reliable target that can be translated as a
new therapeutic treatment option for CAD. This gene was
initially identified by LS and is later found to be linked with
autosomal dominant FH for which causal mutations were
recognized in 2003.22 PCSK9 is responsible for the metabolism
of LDL cholesterol through its role in recycling of the LDL re-
ceptor, such that down regulation of this protein could
become a therapeutic target source for treatment of FH. New
clinical trials in patients with FH have reported that a com-
posite treatment with atorvastatin and evolocumab
(REGN727/SAR236553), a human monoclonal antibody that
blocks the PCSK9 protein, results in a greater reduction of LDL
cholesterol than with atorvastatin alone.35
The GAUSS-Z, a randomized placebo-controlled phase III
trial of evolocumab, reported a favorable efficacy along with
an extremely beneficial toxicity profile for statin intolerant
patients.35 The MENDEL-Z randomized controlled phase III
clinical trial showed that anti-PCSK monotherapy with evo-
locumab produced successive LDL-C down regulation
compared with placebo or ezetimibe, and is well accepted in
patients with hypercholesterolemia.36
Function mutations in APOC3 have been validated in CAD
recently. Mutations that disorganizeAPOC3 function corre-
lated with diminished plasma levels of triglycerides. Carriers
hosting these mutations were found to have a decreased risk
of coronary heart disease.37
In spite of substantial gaps in evidence of genetic testing, a
large number of genomic companies have already
commenced offering direct-to-consumer genetic testing for
CAD. Clinicians faced with such information should carefully
consider the above caveats and challenges. While, evidence
keeps on evolving and adding, standard risk prediction algo-
rithms such as the Framingham risk score and careful
consideration of a familial history of premature CAD should
continue to form the basis of cardiovascular riskassessment.26 As new knowledge becomes available, a judi-
cious blend of clinical risk assessment and proven in-
terventions based on evolving genetic informationwill predict
the much awaited outcomes of CAD in the future.8. Conclusions and future considerations
GWA studies for CAD yielded some remarkably promising
leads in discovering new familial variants associated with MI
and CAD. Further, some potentially novel biologic pathways of
atherogenesis and or thrombosis are also in place from these
studies. With advances in genomic technologies, including
low-cost and economical whole genome sequencing tech-
nologies, additional rare genomic variants will be discovered,
allowing unprecedented insights into the biology of CAD. In
spite of, the very rapid and early successes of GWA studies
and the newly discovered MI risk variants, the role of genetic
data in clinical medicine remains to be comprehensively
established and validated. Genetic information may hold
enormous potential for cardiovascular medicine, but much
work is still in place to delineate the role of this information
into clinical practice and rigorously evaluate its impact in
terms of efficiency, results, and cost effectiveness.
Developing an appropriate targeted therapy for a novel
pathway/mechanism does not take very long time. The time
from discovery of the defective cholesterol receptor gene to
development of first statin took almost 20 years.21 The dis-
covery of 50 genetic risk variants for CAD, and the increased
knowledge of CAD prevention, has catalyzed the search for
improved therapeutic treatments. The increased risk
conferred by these variants is widespread and with advances
in technology, the bench to bedside translation surely
enhance at a rapid pace. Research on the use of genetic in-
formation to improve cardiovascular risk will continue to
progress rapidly as we now know that genetic prediction
through genetic testing will be a reality very soon.Conflicts of interest
All authors have none to declare.r e f e r e n c e s
1. Yeolekar ME. Coronary artery disease in Asian Indians.
J Postgrad Med. 1998;44:26e28.
2. Gupta N, Singh S, Maturu VN, Sharma YP, Gill KD.
Paraoxonase 1 (PON1) polymorphisms, haplotypes and
activity in predicting cad risk in North-West Indian Punjabis.
PloS One. 2011;6:e17805.
3. Bahl VK, Prabhakaran D, Karthikeyan G. Coronary artery
disease in Indians. Indian Heart J. 2001;53:707e713.
4. Murray CJ, Lopez AD. Alternative projections of mortality and
disability by cause 1990e2020: Global Burden of Disease
Study. Lancet. 1997;349:1498e1504.
5. Enas EA, Senthilkumar A, Chennikkara H, Bjurlin MA. Prudent
diet and preventive nutrition from pediatrics to geriatrics:
current knowledge and practical recommendations. Indian
Heart J. 2003;55:310e338.
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 6 6 3e6 7 16706. Chan K, Motterle A, Laxton RC, Ye S. Common variant on
chromosome 9p21 predicts severity of coronary artery
disease. J Am Coll Cardiol. 2011;57:1497e1498. author reply
1498-1499.
7. Lloyd-Jones DM, Nam BH, D'Agostino Sr RB, et al. Parental
cardiovascular disease as a risk factor for cardiovascular
disease in middle-aged adults: a prospective study of
parents and offspring. JAMA: J Am Med Assoc.
2004;291:2204e2211.
8. Myers RH, Kiely DK, Cupples LA, Kannel WB. Parental history
is an independent risk factor for coronary artery disease: the
Framingham Study. Am Heart J. 1990;120:963e969.
9. Samani NJ, Deloukas P, Erdmann J, et al. Large scale
association analysis of novel genetic loci for coronary artery
disease. Arterioscler Thromb Vasc Biol. 2009;29:774e780.
10. Musunuru K, Kathiresan S. Genetics of coronary artery
disease. Annu Rev Genomics Hum Genet. 2010;11:91e108.
11. Roberts R, Stewart AF. Genes and coronary artery disease:
where are we? J Am Coll Cardiol. 2012;60:1715e1721.
12. O'Donnell CJ, Nabel EG. Genomics of cardiovascular disease. N
Engl J Med. 2011;365:2098e2109.
13. McPherson R, Pertsemlidis A, Kavaslar N, et al. A common
allele on chromosome 9 associated with coronary heart
disease. Science (New York, NY). 2007;316:1488e1491.
14. Samani NJ, Raitakari OT, Sipila K, et al. Coronary artery
disease-associated locus on chromosome 9p21 and early
markers of atherosclerosis. Arterioscler Thromb Vasc Biol.
2008;28:1679e1683.
15. Helgadottir A, Thorleifsson G, Magnusson KP, et al. The same
sequence variant on 9p21 associates with myocardial
infarction, abdominal aortic aneurysm and intracranial
aneurysm. Nat Genet. 2008;40:217e224.
16. A genome-wide association study in Europeans and South
Asians identifies five new loci for coronary artery disease. Nat
Genet. 2011;43:339e344.
17. Lieb W, Vasan RS. Genetics of coronary artery disease.
Circulation. 2013;128:1131e1138.
18. Damani SB, Topol EJ. Future use of genomics in coronary
artery disease. J Am Coll Cardiol. 2007;50:1933e1940.
19. Tousoulis D, Papageorgiou N, Androulakis E, Briasoulis A,
Antoniades C, Stefanadis C. Fibrinogen and cardiovascular
disease: genetics and biomarkers. Blood Rev. 2011;25:239e245.
20. Lye SH, Chahil JK, Bagali P, et al. Genetic polymorphisms in
LDLR, APOB, PCSK9 and other lipid related genes associated
with familial hypercholesterolemia in Malaysia. PloS One.
2013;8:e60729.
21. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb
Vasc Biol. 2009;29:431e438.
22. Soutar AK, Naoumova RP. Mechanisms of disease: genetic
causes of familial hypercholesterolemia. Nat Clin Pract
Cardiovasc Med. 2007;4:214e225.
23. Padmanabhan S, Hastie C, Prabhakaran D, Dominczak AF.
Genomic approaches to coronary artery disease. Indian J Med
Res. 2010;132:567e578.
24. Schunkert H, Konig IR, Kathiresan S, et al. Large-scale
association analysis identifies 13 new susceptibility loci for
coronary artery disease. Nat Genet. 2011;43:333e338.
25. Samani NJ, Erdmann J, Hall AS, et al. Genomewide association
analysis of coronary artery disease. N Engl J Med.
2007;357:443e453.
26. Ganesh SK, Arnett DK, Assimes TL, et al. Genetics and
genomics for the prevention and treatment of cardiovascular
disease: update: a scientific statement from the American
Heart Association. Circulation. 2013;128:2813e2851.
27. Kathiresan S, Voight BF, Purcell S, et al. Genome-wide
association of early-onset myocardial infarction with single
nucleotide polymorphisms and copy number variants. Nat
Genet. 2009;41:334e341.28. Samani NJ, Schunkert H. Chromosome 9p21 and
cardiovascular disease: the story unfolds. Circ Cardiovasc
Genet. 2008;1:81e84.
29. Dandona S, Stewart AF, Chen L, et al. Gene dosage of the
common variant 9p21 predicts severity of coronary artery
disease. J Am Coll Cardiol. 2010;56:479e486.
30. Reilly MP, Li M, He J, et al. Identification of ADAMTS7 as a
novel locus for coronary atherosclerosis and association of
ABO with myocardial infarction in the presence of coronary
atherosclerosis: two genome-wide association studies. Lancet.
2011;377:383e392.
31. Shanker J, Perumal G, Rao VS, et al. Genetic studies on the
APOA1-C3-A5 gene cluster in Asian Indians with premature
coronary artery disease. Lipids Health Dis. 2008;7:33.
32. Mallik S, Majumder PP. A two-step genetic study on
quantitative precursors of coronary artery disease in a
homogeneous Indian population: case-control association
discovery and validation by transmission-disequilibrium test.
J Biosci. 2011;36:857e868.
33. Kumar J, Yumnam S, Basu T, et al. Association of
polymorphisms in 9p21 region with CAD in North Indian
population: replication of SNPs identified through GWAS. Clin
Genet. 2011;79:588e593.
34. Lusis AJ. Life after GWAS: functional genomics in vascular
biology. Arterioscler Thromb Vasc Biol. 2012;32:169.
35. Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody
effectively lowers cholesterol in patients with statin
intolerance: the GAUSS-2 randomized, placebo-controlled
phase 3 clinical trial of evolocumab. J Am Coll Cardiol.
2014;63:2541e2548.
36. Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9
monotherapy for hypercholesterolemia: the MENDEL-2
randomized, controlled phase III clinical trial of evolocumab.
J Am Coll Cardiol. 2014;63:2531e2540.
37. The TG and HDL Working Group of the Exome Sequencing
Project, National Heart, Lung, and Blood Institute. Loss-of-
function mutations in APOC3, triglycerides, and coronary
disease. N Engl J Med. 2014;371:32e41.
38. Preuss M, Konig IR, Thompson JR, et al. Design of the
Coronary ARtery DIsease Genome-Wide Replication and
Meta-Analysis (CARDIoGRAM) Study: a Genome-wide
association meta-analysis involving more than 22 000
cases and 60 000 controls. Circ Cardiovasc Genet.
2010;3:475e483.
39. Lu X, Wang L, Chen S, et al. Genome-wide association study
in Han Chinese identifies four new susceptibility loci for
coronary artery disease. Nat Genet. 2012;44:890e894.
40. Deloukas P, Kanoni S, Willenborg C, et al. Large-scale
association analysis identifies new risk loci for coronary
artery disease. Nat Genet. 2013;45:25e33.
41. Maitra A, Shanker J, Dash D, et al. Polymorphisms in the
pituitary growth hormone gene and its receptor associated
with coronary artery disease in a predisposed cohort from
India. J Genet. 2010;89:437e447.
42. Rao VS, Kadarinarasimhiah NB, John S, Hebbagodi S,
Shanker J, Kakkar VV. Usefulness of C-reactive protein as a
marker for prediction of future coronary events in the asian
Indian population: Indian atherosclerosis research study. Int J
Vasc Med. 2010;2010:389235.
43. Rao VS, Khadrinarasimhaih NB, Kanjilal S, Mukerjee M,
Kakkar VV. Genetic contribution to variation in
atherothrombotic phenotypes in the Asian Indian population.
The Indian Atherosclerosis Research Study. Thromb Haemost.
2009;102:379e388.
44. Pulla Reddy B, Srikanth Babu BM, Venkata Karunakar K, et al.
Angiotensin-converting enzyme gene variant and its levels:
risk factors for myocardial infarction in a South Indian
population. Singapore Med J. 2010;51:576e581.
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 6 6 3e6 7 1 67145. Das M, Pal S, Ghosh A. Apolipoprotein E gene polymorphism
and dyslipidaemia in adult Asian Indians: a population based
study from Calcutta, India. Indian J Hum Genet. 2008;14:87e91.
46. Purushothaman S, Ajitkumar VK, Renuka Nair R. Association
of PPARalpha Intron 7 polymorphism with coronary artery
disease: a Cross-Sectional Study. ISRN Cardiol.
2011;2011:816025.47. Nair J, Ghatge M, Kakkar VV, Shanker J. Network analysis of
inflammatory genes and their transcriptional regulators in
coronary artery disease. PloS One. 2014;9:e94328.
48. Mittal G, Gupta V, Haque SF, Khan AS. Effect of angiotensin
converting enzyme gene I/D polymorphism in patients with
metabolic syndrome in North Indian population. Chin Med J.
2011;124:45e48.
